Agile Therapeutics, Inc., a women's healthcare company, focuses on the development and commercialization of prescription contraceptive products for women. Its lead product candidate is Twirla, also known as AG200-15, a once-weekly prescription combination hormonal contraceptive patch, which completed Phase III clinical trials. The company is also developing a pipeline of other transdermal contraceptive products, including AG200-ER, a regimen that allows a woman to extend the length of her cycle; AG200-SP, which is a regimen designed to provide shorter lighter periods; AG200-ER (SmP), a regimen to allow a woman to extend the length of her cycle, as well as experience shorter and lighter periods; and AG890, a progestin-only contraceptive patch intended for use by women who are unable or unwilling to take estrogen. Agile Therapeutics, Inc. was founded in 1997 and is headquartered in Princeton, New Jersey.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:AGRX
CUSIPN/A
Phone609-683-1880
Debt
Debt-to-Equity RatioN/A
Current Ratio2.35
Quick Ratio2.35
Price-To-Earnings
Trailing P/E Ratio-0.59
Forward P/E Ratio-0.82
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$1.06 per share
Price / Book0.51
Profitability
EPS (Most Recent Fiscal Year)($0.91)
Net Income$-28,300,000.00
Net MarginsN/A
Return on Equity-81.74%
Return on Assets-56.48%
Miscellaneous
Employees21
Outstanding Shares34,250,000
Market Cap$18.49
Agile Therapeutics (NASDAQ:AGRX) Frequently Asked Questions
What is Agile Therapeutics' stock symbol?
Agile Therapeutics trades on the NASDAQ under the ticker symbol "AGRX."
How were Agile Therapeutics' earnings last quarter?
Agile Therapeutics Inc (NASDAQ:AGRX) issued its earnings results on Monday, May, 7th. The specialty pharmaceutical company reported ($0.21) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.19) by $0.02. View Agile Therapeutics' Earnings History.
What price target have analysts set for AGRX?
6 Wall Street analysts have issued 12-month target prices for Agile Therapeutics' stock. Their predictions range from $3.00 to $13.00. On average, they expect Agile Therapeutics' stock price to reach $6.25 in the next twelve months. This suggests a possible upside of 1,057.6% from the stock's current price. View Analyst Ratings for Agile Therapeutics.
What is the consensus analysts' recommendation for Agile Therapeutics?
6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Agile Therapeutics in the last year. There are currently 2 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
What are Wall Street analysts saying about Agile Therapeutics stock?
Here are some recent quotes from research analysts about Agile Therapeutics stock:
- 1. HC Wainwright analysts commented, "it as Just Another Delay; Reiterate Buy but Lower to $8 Stock Data 12/21/2017 Price $4.76 Exchange NASDAQ Price Target $8.00 52-Week High $6.62 52-Week Low $2.04 Enterprise Value (M) $131.3 Market Cap (M) $163 Shares Outstanding (M) 34.2 3 Month Avg Volume 267,948 Short Interest (M) 0.30 Balance Sheet Metrics Cash (M) $43.8 Total Debt (M) $12.1 Total Cash/Share $1.28 EPS Diluted Full Year – Dec 2016A 2017E 2018E 1Q (0.27) (0.26)A (0.28) 2Q (0.29) (0.26)A (0.26) 3Q (0.27) (0.22)A (0.29) 4Q (0.18) (0.24) (0.32) FY (1.02) (0.98) (1.16) Revenue ($M) Full Year – Dec 2016A 2017E 2018E 1Q 0.0 0.0A 0.0 2Q 0.0 0.0A 0.0 3Q 0.0 0.0A 0.0 4Q 0.0 0.0 0.0 FY 0.0 0.0 0.0 7 6 5 4 3 2 1 DEC- 16 APR- 17 AUG- 17 DEC- 17 20 15 10 5 0 Vol. (mil) Price Twirla Complete Response Letter surprisingly focused on patch adhesion; we believe the issues are readily addressable. The consensus investor Twirla sticking issue has been around the “high” Phase 3 Pearl Index (implied lower efficacy) vs. prior." (12/22/2017)
- 2. Cantor Fitzgerald analysts commented, "One time when you’re happy to receive a belated Christmas present. The PDUFA date for Twirla is December 26, and we believe it reasonable that an approval will occur around then. We suppose it might be possible that FDA staffers clear their plates before the holiday season. AGRX management has deftly avoided addressing whether labeling discussions have occurred as that would be an indication that FDA approval could be forthcoming." (11/6/2017)
Are investors shorting Agile Therapeutics?
Agile Therapeutics saw a decline in short interest in the month of June. As of June 29th, there was short interest totalling 248,838 shares, a decline of 59.2% from the June 15th total of 609,828 shares. Based on an average daily volume of 379,813 shares, the days-to-cover ratio is presently 0.7 days. Approximately 1.3% of the company's stock are sold short. View Agile Therapeutics' Current Options Chain.
Who are some of Agile Therapeutics' key competitors?
Some companies that are related to Agile Therapeutics include Merrimack Pharmaceuticals (MACK), IMMUTEP LTD/S (IMMP), Advaxis (ADXS), Alimera Sciences (ALIM), Novelion Therapeutics (NVLN), Evofem Biosciences (EVFM), OncoSec Medical (ONCS), Helix Biopharma (HBPCF), Vascular Biogenics (VBLT), Eyenovia (EYEN), Novus Therapeutics (NVUS), Aquinox Pharmaceuticals (AQXP), OASMIA PHARMACE/ADR (OASM), Celsion (CLSN) and IntelGenx Technologies (IGXT).
Who are Agile Therapeutics' key executives?
Agile Therapeutics' management team includes the folowing people:
- Mr. Alfred F. Altomari, Chairman & CEO (Age 59)
- Mr. Scott M. Coiante, CFO & Sr. VP (Age 51)
- Dr. Elizabeth Ijeoma Onyemelukwe Garner, Sr. VP & Chief Medical Officer (Age 50)
- Ms. Mary Coleman, Head of Investor Relations & Corp. Communications
- Mr. Geoffrey P. Gilmore, Gen. Counsel (Age 52)
Has Agile Therapeutics been receiving favorable news coverage?
Media headlines about AGRX stock have been trending somewhat positive recently, according to Accern Sentiment Analysis. Accern identifies positive and negative press coverage by monitoring more than twenty million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Agile Therapeutics earned a news sentiment score of 0.15 on Accern's scale. They also gave news coverage about the specialty pharmaceutical company an impact score of 46.03 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company's share price in the immediate future.
Who are Agile Therapeutics' major shareholders?
Agile Therapeutics' stock is owned by a number of of institutional and retail investors. Top institutional investors include CAXTON CORP (2.00%). Company insiders that own Agile Therapeutics stock include Alfred Altomari and Renee Selman. View Institutional Ownership Trends for Agile Therapeutics.
How do I buy shares of Agile Therapeutics?
Shares of AGRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Agile Therapeutics' stock price today?
One share of AGRX stock can currently be purchased for approximately $0.5399.
How big of a company is Agile Therapeutics?
Agile Therapeutics has a market capitalization of $18.49 million. The specialty pharmaceutical company earns $-28,300,000.00 in net income (profit) each year or ($0.91) on an earnings per share basis. Agile Therapeutics employs 21 workers across the globe.
How can I contact Agile Therapeutics?
Agile Therapeutics' mailing address is 101 POOR FARM ROAD, PRINCETON NJ, 08540. The specialty pharmaceutical company can be reached via phone at 609-683-1880 or via email at [email protected]
MarketBeat Community Rating for Agile Therapeutics (NASDAQ AGRX)
MarketBeat's community ratings are surveys of what our community members think about Agile Therapeutics and other stocks. Vote "Outperform" if you believe AGRX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AGRX will underperform the S&P 500 over the long term. You may vote once every thirty days.
